Advanced search
Publication Cover
Future Neurology Volume 8, 2013 - Issue 5
Submit an article Journal homepage
49
Views
0
CrossRef citations to date
0
Altmetric
Review

The Role of Sphingosine 1-Phosphate Receptors In the Treatment of Demyelinating Diseases

Adam J Pritchard1 Molecular Neuropharmacology, Department of Physiology, School of Medicine, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, IrelandView further author information
&
Kumlesh K Dev1 Molecular Neuropharmacology, Department of Physiology, School of Medicine, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, IrelandCorrespondence[email protected]
View further author information
Pages 569-581 | Published online: 28 Aug 2013

References

  • Matloubian M , LoCG, CinamonG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature427(6972), 355–360 (2004).
  • Zhi L , KimP, ThompsonBDet al. FTY720 blocks egress of t cells in part by abrogation of their adhesion on the lymph node sinus. J. Immunology187(5), 2244–2251 (2011).
  • Pappu R , SchwabSR, CornelissenIet al. promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science316(5822), 295–298 (2007).
  • Kappos L , RadueEW, O‘ConnorPet al. A Placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
  • Takuwa Y , OkamotoY, YoshiokaK, TakuwaN. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim. Biophys. Acta1781(9), 483–488 (2009).
  • Dev KK , MullershausenF, MattesHet al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol. Ther.117(1), 77–93 (2008).
  • Jaillard C , HarrisonS, StankoffBet al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neuroscience25(6), 1459–1469 (2005).
  • Miron VE , LudwinSK, DarlingtonPJet al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol.176(6), 2682–2694 (2010).
  • Sheridan GK , DevKK. S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia60(3), 382–392 (2012).
  • Di Menna L , MolinaroG, Di NuzzoLet al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol. Res.67(1), 1–9 (2012).
  • Sim-Selley LJ , GoforthPB, MbaMUet al. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. J. Neurochem.110(4), 1191–1202 (2009).
  • Osinde M , MullershausenF, DevKK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology52, 1210–1218 (2007).
  • Foster CA , HowardLM, SchweitzerAet al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther.323(2), 469–476 (2007).
  • Choi JW , GardellSE, HerrDRet al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl Acad. Sci. USA108(2), 751–756 (2011).
  • Gonzalez-Cabrera PJ , CahalanSM, NguyenNet al. S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol. Pharmacol.81(2), 166–174 (2012).
  • Cahalan SM , Gonzalez-CabreraPJ, NguyenNet al. Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist. Mol. Pharmacol.83(2), 316–321 (2013).
  • Fatatis A , MillerRJ. Sphingosine and sphingosine 1-phosphate differentially modulate platelet-derived growth factor-BB-induced Ca2+ signaling in transformed oligodendrocytes. J. Biol. Chem.271(1), 295–301 (1996).
  • Nicolay DJ , DoucetteJR, NazaraliAJ. Transcriptional control of oligodendrogenesis. Glia55(13), 1287–1299 (2007).
  • Parras CM , GalliR, BritzOet al. Mash1 specifies neurons and oligodendrocytes in the postnatal brain. EMBO J.23(22), 4495–4505 (2004).
  • Nielsen JA , BerndtJA, HudsonLD, ArmstrongRC. Myelin transcription factor 1 (Myt1) modulates the proliferation and differentiation of oligodendrocyte lineage cells. Mol. Cell. Neurosci.25(1), 111–123 (2004).
  • Qi Y , TanM, HuiCC, QiuM. Gli2 is required for normal SHH signaling and oligodendrocyte development in the spinal cord. Mol. Cell. Neurosci.23(3), 440–450 (2003).
  • Fancy SPJ , ZhaoC, FranklinRJ. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Mol. Cell. Neurosci.27(3), 247–254 (2004).
  • Miron VE , KuhlmannT, AntelJP. Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim. Biophys. Acta1812(2), 184–193 (2011).
  • Baumann N , Pham-DinhD. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev.81(2), 871–927 (2001).
  • Rosenberg SS , PowellBL, ChanJR. Receiving mixed signals: uncoupling oligodendrocyte differentiation and myelination. Cell. Mol. Life Sci.64(23), 3059–3068 (2007).
  • McMorris FA , Dubois-DalcqM. Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. J. Neurosci. Res.21(2–4), 199–209 (1988).
  • Reynolds R , WilkinGP. Development of macroglial cells in rat cerebellum. II. An in situ immunohistochemical study of oligodendroglial lineage from precursor to mature myelinating cell. Development102, 409–425 (1988).
  • Compston A , ColesA. Multiple sclerosis. Lancet372(9648), 1502–1517 (2008).
  • Miller DH , KhanOA, SheremataWAet al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348(1), 15–23 (2003).
  • Cohen JA , BarkhofF, ComiGet al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
  • Rosen H , Gonzalez-CabreraPJ, SannaMG, BrownS. Sphingosine 1-Phosphate Receptor Signaling. Ann. Rev. Biochem.78, 743–768 (2009).
  • Schwab SR , PereiraJP, MatloubianM, XuY, HuangY, CysterJG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science309(5741), 1735–17399 (2005).
  • Pham TH , BalukP, XuYet al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J. Exp. Med.207(1), 17–27 (2010).
  • Schwab SR , CysterJG. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol.8(12), 1295–1301 (2007).
  • Walzer T , ChiossoneL, ChaixJet al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol.8(12), 1337–1344 (2007).
  • Hla T , BrinkmannV. Sphingosine 1-phosphate: physiology and the effects of S1P receptor modulation. Neurology76(8 Suppl. 3), S3–S8 (2011).
  • Rosen H , SannaMG, CahalanSM, Gonzalez-CabreraPJ. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol.28(3), 102–107 (2007).
  • Jiang LI , CollinsJ, DavisRet al. Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J. Biol. Chem.282(14), 10576–10584 (2007).
  • Takashima S , SugimotoN, TakuwaN, OkamotoY. G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc. Res.79(4), 689–697 (2008).
  • IM D , TomuraH, TobeM, SatoK, OkajimaF. Enhancement of sphingosine 1-phosphate-induced phospholipase C activation during G0–G1 transition in rat hepatocytes. J. Pharmacol. Sci.95(2), 284–290 (2004).
  • Bjorklund S , PalmbergS, RaskS, WesterdahlA, TornquistK. Effects of sphingosine 1-phosphate on calcium signaling, proliferation and S1P2 receptor expression in PC Cl3 rat thyroid cells. Mol. Cell. Endocrinol.231(1–2), 65–74 (2005).
  • Mandala S , HajduR, BergstromJet al. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science296(5566), 346–349 (2002).
  • Sanchez T , Estrada-HernandezT, PaikJHet al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem.278(47), 47281–47290 (2003).
  • Mullershausen F , CraveiroLM, ShinYet al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine 1-phosphate receptors. J. Neurochem.102(4), 1151–1161 (2007).
  • Bieberich E . There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells. Neurochem.Res.36(9), 1601–1611 (2011).
  • Miron VE , JungCG, KimHJ, KennedyTE, SolivenB, AntelJP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol.63(1), 61–71 (2008).
  • Brinkmann V , DavisMD, HeiseCEet al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem.277(24), 21453–21457 (2002).
  • Zemann B , KinzelB, MüllerMet al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood107(4), 1454–1458 (2006).
  • Allende ML , SasakiT, KawaiHet al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem.279(50), 52487–52492 (2004).
  • Michaud J , KohnoM, ProiaRL, HlaT. Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FEBS Lett.580(19), 4607–4612 (2006).
  • Gräler MH , GoetzlEJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J.18(3), 551–553 (2004).
  • Oo ML , ChangS, ThangadaSet al. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J. Clin. Invest.121(6), 2290–2300 (2011).
  • Oo ML , ThangadaS, WuMet al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem.282(12), 9082–9089 (2007).
  • Pham THM , OkadaT, MatloubianM, LoCG, CysterJG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity28(1), 122–133 (2008).
  • Lo CG , XuY, ProiaRL, CysterJG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J. Exp. Med.201(2), 291–301 (2005).
  • Sanna MG , LiaoJ, JoEet al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem.279(14), 13839–13848 (2004).
  • Thangada S , KhannaKM, BlahoVAet al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J. Exp. Med.207(7), 1475–1483 (2010).
  • Tarrasón G , AulíM, MustafaSet al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int. Immunopharmacol.11(11), 1773–1779 (2011).
  • Fujii Y , OhtakeH, OnoN, HaraT, SakuraiT, TakahashiS. Lymphopenia induced by a novel selective S1P 1 antagonist structurally unrelated to S1P. Biochim. Biophys. Acta1821(4), 600–606 (2012).
  • Quancard J , BollbuckB, JanserPet al. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune ecephalomyelitis. Chem. Biol.19(9), 1142–1151 (2012).
  • Cahalan SM , Gonzalez-CabreraPJ, NguyenNet al. Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist. Mol. Pharmacol.83(2), 316–321 (2013).
  • Angst D , JanserP, QuancardJet al. An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation. J. Med.Chem.55(22), 9722–9734 (2012).
  • Allende ML , ProiaRL. Sphingosine-1-phosphate receptors and the development of the vascular system. Development1582(1–3), 222–227 (2002).
  • Gräler MH , HuangMC, WatsonS, GoetzlEJ. Immunological effects of transgenic constitutive expression of the type 1 sphingosine 1-phosphate receptor by mouse lymphocytes. J. Immunology174(4), 1997–2003 (2005).
  • Jo E , SannaMG, Gonzalez-CabreraPJet al. S1P1-selective in vivo-active agonists from high- throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol.12(6), 703–715 (2005).
  • Visentin B , VekichJA, SibbaldBJet al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell9(3), 225–238 (2006).
  • Wei SH , RosenH, MatheuMPet al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat. Immunol.6(12), 1228–1235 (2005).
  • Sanna MG , WangS-K, Gonzalez-CabreraPJet al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol.2(8), 434–441 (2006).
  • Davis MD , ClemensJJ, MacdonaldTL, LynchKR. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol.Chem.280(11), 9833–9841 (2005).
  • Awad AS , YeH, HuangLet al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Renal Physiol.290(6), F1516–F1524 (2006).
  • Foss J r. FW, Snyder AH, Davis MD et al. Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg. Med. Chem.15(2), 663–677 (2007).
  • Mullershausen F , ZecriF, CetinC, BillichA, GueriniD, SeuwenK. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat. Chem. Biol.5(6), 428–435 (2009).
  • Healy LM , SheridanGK, PritchardAJ, RutkowskaA, MullershausenF, DevKK. Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br. J. Pharmacol.169(5), 1114–1129 (2013).
  • O‘Sullivan C , DevKK. The structure and function of the S1P1 receptor. Trends Pharmacol. Sci.34(7), 401–412 (2013).
  • Liao JJ , HuangMC, GoetzlEJ. Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J. Immunology178(9), 5425–5428 (2007).
  • Means CK , MiyamotoS, ChunJ, BrownJH. S1P1 receptor localization confers selectivity for Gi-mediated camp and contractile responses. J. Biol. Chem.283(18), 11954–11963 (2008).
  • Forrest M , SunS, HajduRet al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther.309(2), 758–768 (2004).
  • Yu N , Lariosa-WillinghamKD, LinFF, WebbM, RaoTS. Characterization of lysophosphatidic acid and sphingosine 1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia45(1), 17–27 (2004).
  • Hida H , NaganoS, TakedaM, SolivenB. Regulation of mitogen-activated protein kinases by sphingolipid products in oligodendrocytes. J. Neurosci.19(17), 7458–7467 (1999).
  • Saini HS , CoelhoRP, GoparajuSKet al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J. Neurochem.95(5), 1298–12310 (2005).
  • Kumar S , KahnMA, DinhL, de VellisJ. NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo. J. Neurosci. Res.54(6), 754–765 (1998).
  • Kahn MA , KumarS, LieblD, ChangR, ParadaLF, De Vellis J. Mice lacking NT-3, and its receptor TrkC, exhibit profound deficiencies in CNS glial cells. Glia26(2), 153–165 (1999).
  • Kumar S , BiancottiJC, YamaguchiM, De Vellis J. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Neurochem. Res.32(4–5), 783–797 (2007).
  • Waters CM , LongJ, GorshkovaIet al. Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J.20(3), 509–511 (2006).
  • Soliven B , MaL, BaeH, AttaliB, SobkoA, IwaseT. PDGF upregulates delayed rectifier via Src family kinases and sphingosine kinase in oligodendroglial progenitors. Am. J. Physiol. Cell. Physiol.284(1), C85–C93 (2003).
  • Igarashi J , MichelT. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction. J. Biol. Chem.275(41), 32363–32370 (2000).
  • Jung CG , KimHJ, MironVEet al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia55(16), 1656–1667 (2007).
  • Mattes H , DevKK, BouhelalRet al. Design and synthesis of selective and potent orally active S1P5 agonists. Chem. Med. Chem.5(10), 1693–1696 (2010).
  • Miron VE , HallJA, KennedyTE, SolivenB, AntelJP. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol.173(4), 1143–1152 (2008).
  • Coelho RP , PayneSG, BittmanR, SpiegelS, Sato-BigbeeC. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther.323(2), 626–635 (2007).
  • Sato K , MalchinkhuuE, HoriuchiYet al. HDL-like lipoproteins in cerebrospinal fluid affect neural cell activity through lipoprotein-associated sphingosine 1-phosphate. Biochem. Biophys. Res. Commun.359(3), 649–654 (2007).
  • Qin J , BerdyshevE, GoyaJ, NatarajanV, DawsonG. Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis. J. Biol. Chem.285(19), 14134–14143 (2010).
  • Novgorodov AS , El-AlwaniM, BielawskiJ, ObeidLM, GudzTI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J.21(7), 1503–1514 (2007).
  • Jackson SJ , GiovannoniG, BakerD. Fingolimod modulates microglial activation to augment markers of remyelination. J. Neuroinflammation8(1), 76 (2011).
  • Kim HJ , MironVE, DukalaDet al. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J.25(5), 1509–1518 (2011).
  • Hu Y , LeeX, JiBet al. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo. Mol. Cell. Neurosci.48(1), 72–81 (2011).
  • Balatoni B , StorchMK, SwobodaE-Met al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull.74(5), 307–316 (2007).
  • Graeler M , GoetzlEJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J.16(14), 1874–1878 (2002).
  • Cinamon G , MatloubianM, LesneskiMJet al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat. Immunol.5(7), 713–720 (2004).
  • Hughes JE , SrinivasanS, LynchKRet al. Sphingosine-1-Phosphate Induces an Anti-inflammatory Phenotype in Macrophages. Circ. Res.102(8), 950–958 (2008).
  • Kays JS , LiC, NicolGD. Expression of sphingosine 1-phosphate receptors in the rat dorsal root ganglia and defined single isolated sensory neurons. Physiol. Genomics44(18), 889–901 (2012).
  • Rao TS , Lariosa-WillinghamKD, LinF-Fet al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res.990(1–2), 182–194 (2003).
  • Tham CS , LinFF, RaoTS, YuN, WebbM. Microglial activation state and lysophospholipid acid receptor expression. Int. J. Dev. Neurosci.21(8), 431–443 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.